{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:50:57Z","timestamp":1791553857319,"version":"4.3.4"},"reference-count":165,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.trsl.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T11:36:41Z","timestamp":1636717001000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions"],"prefix":"10.1016","volume":"241","author":[{"given":"Michael J.","family":"Peluso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Donatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Henrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2021.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0002","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0003","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237548","article-title":"Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in relation to clinical data","volume":"15","author":"Naaber","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.006_bib0005","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.cell.2020.10.051","article-title":"Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production","volume":"183","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.006_bib0006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.trsl.2021.11.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240502","article-title":"Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019","volume":"15","author":"Kowitdamrong","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.006_bib0008","article-title":"Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections","author":"Lei","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.trsl.2021.11.006_bib0009","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti\u2013SARS-CoV-2 antibodies in persons with mild Covid-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiaa659","article-title":"Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients","volume":"223","author":"Muecksch","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing antibody titres in SARS-CoV-2 infections","volume":"12","author":"Lau","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.006_bib0013","doi-asserted-by":"crossref","first-page":"eabe0367","DOI":"10.1126\/sciimmunol.abe0367","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"Iyer","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3409","article-title":"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay","volume":"7","author":"Peluso","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.trsl.2021.11.006_bib0016","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.trsl.2021.11.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.01.005","article-title":"Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study","author":"L'Huillier","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trsl.2021.11.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/trf.16555","article-title":"SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance","author":"Di Germanio","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.trsl.2021.11.006_bib0019","article-title":"Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after Infection","author":"Yao","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-021-07057-0","article-title":"Long-term persistence of neutralizing antibodies to SARS-CoV-2 following infection","author":"Wisnivesky","year":"2021","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0021","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1038\/s41467-021-22958-8","article-title":"Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival","volume":"12","author":"Dispinseri","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.006_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.661187","article-title":"Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors","volume":"12","author":"Goto","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0023","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jinf.2020.09.015","article-title":"Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection","volume":"82","author":"Orth-H\u00f6ller","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.trsl.2021.11.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202617","article-title":"Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection","volume":"218","author":"Le Bert","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.trsl.2021.11.006_bib0026","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.006_bib0027","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0028","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.006_bib0029","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.trsl.2021.11.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109518","article-title":"Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms","volume":"36","author":"Peluso","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.trsl.2021.11.006_bib0031","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf7517","article-title":"T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals","volume":"13","author":"Bilich","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0032","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41467-021-21155-x","article-title":"Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-04060-7","article-title":"Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination","author":"Cho","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.006_bib0034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.006_bib0035","doi-asserted-by":"crossref","first-page":"n99","DOI":"10.1136\/bmj.n99","article-title":"What we know about covid-19 reinfection so far","volume":"372","author":"Stokel-Walker","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2021.11.006_bib0036","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.15585\/mmwr.mm7032e1","article-title":"Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination - kentucky, May-June 2021","volume":"70","author":"Cavanaugh","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.trsl.2021.11.006_bib0037","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.trsl.2021.11.006_bib0038","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","author":"Tarke","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.trsl.2021.11.006_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.592629","article-title":"Dynamics of CD4 T Cell and antibody responses in COVID-19 patients with different disease severity","volume":"7","author":"Koblischke","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009761","article-title":"SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence","volume":"17","author":"Boppana","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2021.11.006_bib0041","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.trsl.2021.11.006_bib0042","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41590-020-00838-5","article-title":"Deciphering the ins and outs of SARS-CoV-2-specific T cells","volume":"22","author":"Perez-Potti","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0043","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0044","article-title":"Negligible impact of SARS-CoV-2 variants on CD4\u00a0+\u00a0and CD8\u00a0+\u00a0T cell reactivity in COVID-19 exposed donors and vaccinees","author":"Tarke","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.trsl.2021.11.006_bib0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41577-020-00460-4","article-title":"Cross-reactive memory T cells and herd immunity to SARS-CoV-2","volume":"20","author":"Lipsitch","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0046","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe8063","article-title":"The known unknowns of T cell immunity to COVID-19","volume":"5","author":"Karlsson","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0047","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0048","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.immuni.2020.11.016","article-title":"Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19","volume":"53","author":"Bacher","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.trsl.2021.11.006_bib0049","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1038\/s41467-021-21856-3","article-title":"T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses","volume":"12","author":"Ogbe","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.trsl.2021.11.006_bib0050","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe8065","article-title":"Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans","volume":"7","author":"Klasse","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.trsl.2021.11.006_bib0051","first-page":"901","article-title":"SARS-CoV-2 variant antibodies wane 6 months after vaccination","volume":"326","author":"Abbasi","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.11.006_bib0052","article-title":"Covid-19 breakthrough infections in vaccinated health care workers","volume":"385","author":"Jung","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0053","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0054","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 vaccine among U.S. Health Care Personnel","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0056","article-title":"Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution","author":"Ke","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.trsl.2021.11.006_bib0057","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody Persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0058","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/cells10081942","article-title":"Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162b2; a prospective study in 283 health workers","volume":"10","author":"Terpos","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.trsl.2021.11.006_bib0059","article-title":"Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients","volume":"131","author":"Stock","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.11.006_bib0060","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.16599","article-title":"Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients","volume":"21","author":"Caballero-Marcos","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2021.11.006_bib0061","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1111\/ajt.16570","article-title":"SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients","volume":"21","author":"Fav\u00e0","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2021.11.006_bib0062","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/TP.0000000000003523","article-title":"COVID-19 and solid organ transplantation: a review article","volume":"105","author":"Azzi","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.trsl.2021.11.006_bib0063","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16768","article-title":"Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients","author":"Herrera","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2021.11.006_bib0064","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1111\/ajt.16702","article-title":"Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients","volume":"21","author":"Miele","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2021.11.006_bib0065","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.11.006_bib0066","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1097\/TP.0000000000003780","article-title":"Safety and reactogenicity of 2 Doses of SARS-CoV-2 vaccination in solid organ transplant recipients","volume":"105","author":"Ou","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.trsl.2021.11.006_bib0067","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single Dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.trsl.2021.11.006_bib0068","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150175","article-title":"Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.11.006_bib0069","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.7326\/L21-0282","article-title":"Safety and immunogenicity of a third Dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series","volume":"174","author":"Werbel","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0070","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003934","article-title":"Antibody response to a fourth Dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series","author":"Alejo","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.trsl.2021.11.006_bib0071","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0072","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 Messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0073","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2021.11.006_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.06.036","article-title":"BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel","author":"Brosh-Nissimov","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trsl.2021.11.006_bib0075","doi-asserted-by":"crossref","first-page":"ofab393","DOI":"10.1093\/ofid\/ofab393","article-title":"Discordant virus-specific antibody levels, antibody neutralization capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 vaccination in a patient with connective tissue disease","volume":"8","author":"Peluso","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0076","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0077","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0078","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","author":"Apostolidis","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0079","doi-asserted-by":"crossref","unstructured":"Sabatino JJ, Mittl K, Rowles W, et al. Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. medRxiv2021. doi:10.1101\/2021.09.10.21262933","DOI":"10.1101\/2021.09.10.21262933"},{"key":"10.1016\/j.trsl.2021.11.006_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.trsl.2021.11.006_bib0081","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.3609","article-title":"Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis","author":"Disanto","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00251-4","article-title":"Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0083","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16818","article-title":"Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients","author":"Schmidt","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2021.11.006_bib0084","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients","author":"Hall","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trsl.2021.11.006_bib0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC Neurol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0086","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S2352-3018(21)00072-2","article-title":"SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study","volume":"8","author":"Spinelli","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.trsl.2021.11.006_bib0087","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/jmv.26556","article-title":"COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2","volume":"93","author":"Mondi","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0088","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.080","article-title":"Seroprevalence of anti-SARS-CoV2 antibodies in Umbrian persons living with HIV","volume":"12","author":"Papalini","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0089","doi-asserted-by":"crossref","unstructured":"Liu Y, Xiao Y, Wu S, et al. People Living with HIV Easily lose their Immune Response to SARS-CoV-2: Result From A Cohort of COVID-19 Cases in Wuhan, China. 2021. doi:10.21203\/rs.3.rs-543375\/v1","DOI":"10.21203\/rs.3.rs-543375\/v1"},{"key":"10.1016\/j.trsl.2021.11.006_bib0090","article-title":"The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with HIV","author":"Woldemeskel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0091","article-title":"Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV","author":"Ruddy","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0092","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/cei.12619","article-title":"T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi, Kenya","volume":"181","author":"Buechler","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0093","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005219","article-title":"CD4\/CD8 Ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients","volume":"10","author":"Avelino-Silva","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0094","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1097\/QAD.0000000000001963","article-title":"Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients","volume":"32","author":"Colin de Verdiere","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0095","doi-asserted-by":"crossref","first-page":"e79816","DOI":"10.1371\/journal.pone.0079816","article-title":"Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation","volume":"8","author":"Parmigiani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.006_bib0096","first-page":"157","article-title":"Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions","volume":"11","author":"van den Berg","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.trsl.2021.11.006_bib0097","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/clinids\/21.5.1197","article-title":"Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus","volume":"21","author":"Kroon","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0098","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0099","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine Storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.trsl.2021.11.006_bib0101","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ajh.25829","article-title":"Hematological findings and complications of COVID-19","volume":"95","author":"Terpos","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0102","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0103","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.4049\/jimmunol.181.8.5490","article-title":"T cell responses to whole SARS coronavirus in humans","volume":"181","author":"Li","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13613-020-00798-x","article-title":"Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients","volume":"11","author":"Lavillegrand","year":"2021","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.trsl.2021.11.006_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242400","article-title":"C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19","volume":"15","author":"Sharifpour","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.006_bib0106","unstructured":"Tobias Herold MD, Arnreich C, Hellmuth JC, Matthias Klein MD, Tobias Weinberger MD. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. https:\/\/www.allergy.org.au\/images\/stories\/about\/attach-IL-6_as_a_marker_of_outcome_in_COVID-19.pdf"},{"key":"10.1016\/j.trsl.2021.11.006_bib0107","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.006_bib0109","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41591-020-1038-6","article-title":"A dynamic COVID-19 immune signature includes associations with poor prognosis","volume":"26","author":"Laing","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.trsl.2021.11.006_bib0111","first-page":"e6","article-title":"Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19","volume":"81","author":"Liu","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.trsl.2021.11.006_bib0112","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jmv.25819","article-title":"Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis","volume":"92","author":"Lagunas-Rangel","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0113","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/infdis\/jiaa150","article-title":"Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia","volume":"221","author":"Wang","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0114","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.trsl.2021.11.006_bib0115","doi-asserted-by":"crossref","first-page":"ofaa574","DOI":"10.1093\/ofid\/ofaa574","article-title":"Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma","volume":"8","author":"Bonny","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0116","doi-asserted-by":"crossref","first-page":"ofab156","DOI":"10.1093\/ofid\/ofab156","article-title":"Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients","volume":"8","author":"Ong","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0117","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","article-title":"Soluble markers of inflammation and coagulation but not T-cell activation predict non\u2013AIDS-defining morbid events during suppressive antiretroviral treatment","volume":"210","author":"Tenorio","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2021.11.006_bib0119","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","author":"Nalbandian","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","article-title":"High-dimensional characterization of post-acute sequelae of COVID-19","volume":"594","author":"Al-Aly","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2021.11.006_bib0121","author":"Ayoubkhani","year":"2021","journal-title":"Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics"},{"key":"10.1016\/j.trsl.2021.11.006_bib0122","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01433-3","article-title":"Long COVID in a prospective cohort of home-isolated patients","author":"Blomberg","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0123","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab411","article-title":"Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study","author":"Horton","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0124","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/s41423-020-00550-2","article-title":"A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract","volume":"17","author":"Hu","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0125","article-title":"Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study","volume":"6","author":"Augustin","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.trsl.2021.11.006_bib0126","article-title":"Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence","author":"Talla","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.trsl.2021.11.006_bib0127","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab490","article-title":"Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection","author":"Peluso","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0128","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/infdis\/jiu238","article-title":"Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection","volume":"210","author":"Hunt","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0129","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/QAD.0000000000001579","article-title":"Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals","volume":"31","author":"Gianella","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0130","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/cts.12953","article-title":"SARS-CoV-2 infection as a trigger of autoimmune response","volume":"14","author":"Sacchi","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.trsl.2021.11.006_bib0131","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00415-020-10108-x","article-title":"Immune-mediated neurological syndromes in SARS-CoV-2-infected patients","volume":"268","author":"Guilmot","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0132","article-title":"Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms","volume":"2","author":"Song","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0133","article-title":"Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study","author":"See\u00dfle","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0134","article-title":"Lack of antinuclear antibodies in convalescent COVID-19 patients with persistent symptoms","author":"Peluso","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0135","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2021.11.006_bib0136","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMc2031364","article-title":"Persistence and evolution of SARS-CoV-2 in an immunocompromised host","volume":"383","author":"Choi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0137","doi-asserted-by":"crossref","first-page":"m1443","DOI":"10.1136\/bmj.m1443","article-title":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study","volume":"369","author":"Zheng","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.trsl.2021.11.006_bib0138","article-title":"Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?","volume":"12","author":"O'Donnell","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.708149","article-title":"Persistent systemic microbial translocation and intestinal damage during coronavirus disease-19","volume":"12","author":"Oliva","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/infdis\/jiw173","article-title":"Interleukin 6 is a stronger predictor of clinical events than high-sensitivity c-reactive protein or D-dimer during HIV infection","volume":"214","author":"\u00c1H","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0141","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1097\/QAD.0000000000001149","article-title":"Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy","volume":"30","author":"Hsu","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0142","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/cid\/ciw409","article-title":"Inflammatory biomarkers and mortality risk among HIV-suppressed men: a multisite prospective cohort study","volume":"63","author":"Wada","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0143","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/cid\/civ840","article-title":"CD8 T-Cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection","volume":"62","author":"Freeman","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0144","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11904-016-0297-9","article-title":"Partners in crime: the role of CMV in immune dysregulation and clinical outcome during HIV infection","volume":"13","author":"Freeman","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.trsl.2021.11.006_bib0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0146","doi-asserted-by":"crossref","first-page":"e16103","DOI":"10.1371\/journal.pone.0016103","article-title":"Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States","volume":"6","author":"Simanek","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2021.11.006_bib0147","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005025","article-title":"Cytomegalovirus infection and relative risk of cardiovascular disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): a meta-analysis of prospective studies up to 2016","volume":"6","author":"Wang","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.trsl.2021.11.006_bib0148","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0149","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.594495","article-title":"Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2","volume":"7","author":"Salamanna","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0150","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0151","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab121","article-title":"Gag p24 is a marker of HIV expression in tissues and correlates with immune response","author":"Wu","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0152","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1172\/JCI126714","article-title":"HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy","volume":"129","author":"McManus","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.trsl.2021.11.006_bib0153","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4077","article-title":"Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells","volume":"11","author":"Nguyen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0154","doi-asserted-by":"crossref","first-page":"25891","DOI":"10.1073\/pnas.1910334116","article-title":"Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors","volume":"116","author":"Patro","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2021.11.006_bib0155","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01270-19","article-title":"Impact of antiretroviral therapy duration on HIV-1 infection of T Cells within anatomic sites","volume":"94","author":"Lee","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002417","article-title":"HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study","volume":"14","author":"Henrich","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.trsl.2021.11.006_bib0157","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/infdis\/jix039","article-title":"Human immunodeficiency virus persistence and T-Cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy","volume":"215","author":"Khoury","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trsl.2021.11.006_bib0158","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/QAD.0000000000002684","article-title":"Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents","volume":"34","author":"Telwatte","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007357","article-title":"Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency","volume":"14","author":"Telwatte","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.trsl.2021.11.006_bib0160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAD.0000000000000166","article-title":"A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells","volume":"28","author":"Yukl","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0161","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/QAD.0b013e328362692f","article-title":"Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers","volume":"27","author":"Hatano","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0162","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COH.0000000000000688","article-title":"Eliminating HIV reservoirs for a cure: the issue is in the tissue","volume":"16","author":"Busman-Sahay","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.trsl.2021.11.006_bib0163","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.683396","article-title":"Situ characterization of human lymphoid tissue immune cells by multispectral confocal imaging and quantitative image analysis; implications for HIV reservoir characterization","volume":"12","author":"Moysi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trsl.2021.11.006_bib0164","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1369\/0022155418756848","article-title":"Elucidating the burden of HIV in tissues using multiplexed immunofluorescence and in situ hybridization: methods for the single-cell phenotypic characterization of cells harboring HIV in situ","volume":"66","author":"Vasquez","year":"2018","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.trsl.2021.11.006_bib0165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-1946-0","article-title":"Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells","volume":"578","author":"McBrien","year":"2020","journal-title":"Nature"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421002693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524421002693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T12:45:05Z","timestamp":1761828305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524421002693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":165,"alternative-id":["S1931524421002693"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2021.11.006","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}